Sihuan Pharmaceutical Holdings Group Ltd. · HKEX:460
Sihuan Pharmaceutical — H1 2024 Earnings Presentation
27 slides from Sihuan Pharmaceutical's earnings presentation, August 2024
Slide 1: 2024 Interim Results Presentation (brief version)
Sihuan Pharmaceutical Holdings Group Ltd. 四环医药控股集团有限公司 (incorporated in Bermuda with limited liability) （于百慕达注册成立之有限公司) Stock Code 股份代号：0460 2024 Interim Results Presentation (brief version) August 2024 Building China’s Leading Medical Aesthetic and Biopharmaceutical Company with Rigor and Innovatio
Slide 2: Disclaimer
Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase sec
Slide 3: Promoting Sihuan Pharm's 2.0 Version in Full Speed
Promoting Sihuan Pharm’s 2.0 Version in Full Speed Industrial upgrade and develop to leading medical aesthetic and innovative pharmaceutical company Category 01 Company Overview 02 Meiyan Space Business Overview 03 Interim Financial Review 04 Appendix 3
Slide 4: Building China's Leading Medical Aesthetic and Biopharmaceutical Company
Building China’s Leading Medical Aesthetic and Biopharmaceutical Company with Rigor and Innovation of a Pharmaceutical Company Insist in the dual wheel drive of “medical aesthetic+innovative pharmaceutical”, successfully transform and upgrade to innovation Revenue Segment Profit Revenue Segment Loss
Slide 5: 2024 Jan-Aug Milestone
2024 Jan-Aug Milestone During the period, multiple products approved for launch, insulin aspart series won the bid of specialsing renewal in insulin procurement, Anaprazole Sodium was successfully commercialized • Ganagliflozin Proline Tablets • Sylfirm X, a dual-wave RF • Sitagliptin Phosphate • In
Slide 6: New Products Approved for Launch during Jan to Aug 2024
New Products Approved for Launch during Jan to Aug 2024 A total of 16 new products were approved for launch, bring new momentum to future revenue growth Class III SYLFIRM X Dual-wave RF Microneedle medical device Liquid Dressing • The world's first FDA and NMPA-approved dual- • Bipolar non-insulatio
Slide 7: 60+ Medical Aesthetic Products and 50+ Innovative/Biological Drugs
60+ Medical Aesthetic Products and 50+ Innovative/Biological Drugs The pipeline includes multiple blockbuster medical aesthetic products & rich / high-value biopharmaceutical products Category Therapy Area Product Name Company Business Pre-clinical Clinical Registration Launch Shaping Botulinum toxi
Slide 8: Investment highlights of Sihuan Pharm
Investment highlights of Sihuan Pharm Rich innovative China’s leading integrated Fast capability in drug/biologics products medical aesthetic platform commercialization pipeline Building China’s leading medical aesthetic platform Adhering to the upgrading and transformation to High efficiency, low c
Slide 9: Practicing Corporate Social Responsibility, Protecting Human Health
Practicing Corporate Social Responsibility, Protecting Human Health Sihuan Pharmaceutical received several awards for ESG management ESG Innovative ESG Exemplary ESG Pioneer Best ESG Award The 13th Philanthropy Festival The 7th IRSC Chinese Practices Enterprise Award 2023 Outstanding IR Gelonghui Ji
Slide 10: Development Goals and Strategies
Development Goals and Strategies Focus on the two-wheel drive strategy of “innovative pharmaceutical+medical aesthetic”, accelerate the launch of innovative drugs and product iteration for generics New Business： New Business: Traditional business Medical Aesthetic Innovative medicine Generic medicin
Slide 11: Meiyan Space
New Business Meiyan Space Building China’s Leading Medical Aesthetic Company 11
Slide 12: Company Highlights
Company Highlights Sihuan Medical Aesthetic Meiyan Space: Building a leading medical aesthetic company with a rich product matrix with the rigorous innovation of a pharmaceutical company. Rich product pipeline covering life-cycle Rich experiences in production of high- needs of beauty lovers end gen
Slide 13: Building a complete medical aesthetic product matrix through strong R&D and BD capabilities
Building a complete medical aesthetic product matrix through strong R&D and BD capabilities A rich product pipeline that covers the needs of beauty lovers throughout their life cycle Commercializa Business Category Product Name Pre-clinical Clinical-Registration tion including: products under R&D: C
Slide 14: Professional medical aesthetic sales team, and a nationwide sales network
Professional medical aesthetic sales team, and a nationwide sales network Optimize the marketing strategy, strengthen the cooperation with leading institutions, increase distributors in the blank area, and successfully promote the business upgrading and development of marketing version 3.0 360+ city
Slide 15: The 3.0 Era of Medical Aesthetic Fine-tuned Operation (I)
The 3.0 Era of Medical Aesthetic Fine-tuned Operation (I) High-quality marketing activities continue to provide institutions with high-quality, efficient services and solutions. The new product launch of Sylfirm X appeared in a number of authoritative industrial conferences, assisting rapid commerci
Slide 16: The 3.0 Era of Medical Aesthetic Fine-tuned Operation (II)
The 3.0 Era of Medical Aesthetic Fine-tuned Operation (II) Meiyan Space adheres to the “essence of medicine”, through the dialogue and cooperation with industry KOL, from academic aspect to show the differentiated value of the product, and to create a benchmark in the medical aesthetic industry Nati
Slide 17: Main medical aesthetic products approved for launch
Main medical aesthetic products approved for launch Letybo® PersnicaTM Botulinum toxin Modified sodium SYLFIRM XTM type A for hyaluronate gel Dual-wave RF Injection for injection Microneedle Specification：100U/vial， Specification：1x1ml 50U/vial High quality High effect Strong support High elasticity
Slide 18: Interim Financial Review
DOP Es 25 SihuanPharm Interim Financial Review 18
Slide 19: Interim Financial Review 2024
Interim Financial Review 2024 The medical aesthetics business has grown rapidly. Many products in the R&D pipeline were approved for launch. R&D expenses dropped significantly. Balance of cash and cash Revenue from the medical Revenue from the innovative Revenue from the generic Total revenue of the
Slide 20: Interim operating profit of the Group: achieve profit of RMB109 million
Interim operating profit of the Group：achieve profit of RMB109 million The revenue and profit from the medical aesthetics business grew rapidly, while the traditional generic medicine business was still in the adjustment period. The R&D expense began to decline year by year. In RMB million 400 357 2
Slide 21: Revenue from medical aesthetics business achieved high growth
The revenue from medical aesthetics business achieved high growth: approximately RMB129 million, representing a year-on-year increase of 66.4% The upgraded marketing strategies achieved promising result. The products are highly recognised in the market and therefore driving significantly growth in t
Slide 22: Revenue from generic medicine business decreased
Revenue from generic medicine business decreased：approximately RMB597 million, representing a year-on-year decreased of 29.4% Due to the multiple impacts of industrial policies, some generic medicine experienced declines in price and sales and was still in the adjustment period. In RMB million Segme
Slide 23: R&D expense started to decline
R&D expense started to decline : approximately RMB 196 million, representing 31.2% of revenue from generic medicine and innovative and other medicine Continuing to invest heavily in R&D promotes rapid transformation, upgrading and development of the group’s generic medicine business to innovative an
Slide 24: Solid financial position: cash and deposits of RMB4,971 million
Solid financial position：Cash and cash equivalents, wealth management products, pledged deposits and time deposits in total of RMB4,971 million Operating cash flow maintained net cash inflow position Analysis of cashflow movement in interim period 2024 In RMB million 6,000 -163 5,000 524 • Net cash
Slide 25: Appendix
Appendix 25
Slide 26: Milestones
Milestones • Letybo approved for launch in China, it is the fourth • Non-PVC solid-liquid dual chamber bags and Midazolam • Hainan Sihuan Pharmaceutical Co., Ltd. Founded botulinum toxin product approved in China and the first Oromucosal Solution were included in the NRDL • In Forbes China 2010, ran
Slide 27: Thank you!
Thank you！ Sihuan Pharm IR Dept ir.sihuanpharm.com E: ir@sihuanpharm.com 27
Sihuan Pharmaceutical Holdings Group — H1 2024 Earnings Presentation on 6ix